株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオバンキング:技術と世界市場

Biobanking: Technologies and Global Markets

発行 BCC Research 商品コード 204227
出版日 ページ情報 英文 163 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
バイオバンキング:技術と世界市場 Biobanking: Technologies and Global Markets
出版日: 2016年11月30日 ページ情報: 英文 163 Pages
概要

世界のバイオバンキング技術市場は、2016年の1,982億米ドルから、2021年には2,402億米ドルまで拡大すると見られています。市場は、2016年~2021年のCAGR (複合年間成長率) で、3.9%の成長が予測されています。

当レポートでは、世界のバイオバンク市場について調査分析し、概要、市場動向と予測、市場内訳、新製品開発、主要企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 産業の現状
  • バイオバンキングのプロセス
  • 歴史的背景
  • バイオバンクの成長促進要因
  • バイオバンクの成長抑制要因
  • バイオバンキングの動向と予測
  • 将来のバイオメディカル創薬におけるバイオバンクの役割

第4章 バイオバンク応用の概要

  • バイオマーカー
  • がんの機会
  • 心血管疾患の機会
  • 神経疾患の機会
  • 免疫学の機会
  • その他のバイオバンクの機会

第5章 世界のバイオバンクの現状

  • 概要
  • 米国のバイオバンク
  • 欧州のバイオバンク
  • その他の地域のバイオバンク

第6章 疾患に基づくバイオバンク

  • 疾患に基づくバイオバンクの成長
  • がんバイオバンク
  • 健康標本バイオバンク
  • 提携ネットワーク

第7章 人口に基づくバイオバンク

  • イントロダクション
  • 人口に基づくバイオバンクの種類
  • コホート研究
  • 人口に基づくバイオバンクの設立者
  • 国による人口に基づくバイオバンク

第8章 営利目的のバイオバンク企業

  • 委託バイオバンクとサービス提供者
  • バイオマーカー創薬企業
  • 医薬品収集
  • 研究提携
  • 臨床試験

第9章 バイオバンクの限界

  • 標本の変動性
  • 標本の品質
  • 整合性を高める努力
  • バイオバンク改善の取り組み

第10章 規制動向、知的財産、倫理的考察

  • イントロダクション
  • FDAの役割
  • 規制の枠組みの現状
  • インフォームドコンセント
  • 脱退と所有
  • 機密保持
  • 商業化
  • バイオマーカー応用に対するFDAガイドライン
  • 欧州医薬品庁 (EMA)
  • 知的財産と競合ポジショニング
  • 倫理的考察
  • 規制関係

第11章 バイオバンク市場予測:セグメント・地域別

  • サマリー
  • 地域別構成

第12章 バイオマーカー利用の概要

  • 大腸がん
  • 乳がん
  • 肺がん
  • 前立腺がん
  • 卵巣がん
  • 心血管系
  • 中枢神経系
  • 自己免疫疾患
  • 免疫学

第13章 企業プロファイル

目次
Product Code: BIO084B

The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.

This report provides:

  • An overview of the global markets for biobanking, the storage of biological samples for the future.
  • Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
  • Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
  • Breakdowns of the biobanking market by product, disease category, and geographic region or country.
  • New products approved by the FDA, and those products expected to be approved within the forecast period.
  • Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
  • Profiles of the manufacturers of leading products, and their specific product strategies are outlined.

image1

REPORT SCOPE

SCOPE OF REPORT

This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report's release.

Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report. The competitive market environment is evaluated with a unique emphasis on the effect of the new technologies and products on the prevailing patient care standard. Emerging companies and current leaders in the market are profiled and discussed in detail.

Market figures are founded on the revenue level of the manufacturers and forecast done in the 2016-dollar value. Forecast figures exclude inflation. Parameters like the introduction of new products, forecast sales for prevailing products, expanded indications for prevailing products and forecasted changes in the rates of diagnosis, prevalence and scripting for specific diseases are considered when assessing trends.

Forecasts featured in this report for the period between 2016 and 2021 are based on disease category, product and company. The study is organized for an overview of the biobanks market by geography, company and product. The projections are based on country or geographic region. For every disease sub-segment, the global market is evaluated and data provided.

Consumables that do not require prescription from a physician like over-the-counter (OTC) drugs are not covered in this report.

Sales figures are in U.S. dollars, with each reflecting change in revenue performance due to currency fluctuations. Variations in local currencies, however, are not accounted for by the revenue figures.

Unless pointed out, all data on market share in the report are on a global basis.

ANALYST'S CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • ANALYST'S CREDENTIALS
  • METHODOLOGY AND INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 ($ BILLIONS)

CHAPTER 3 OVERVIEW

  • CURRENT STATE OF THE INDUSTRY
  • THE PROCESS OF BIOBANKING
  • HISTORICAL CONTEXT
    • SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS
    • TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015
    • TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021
    • TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)
      • Modern Biobanks
    • BIOBANKING COSTS
  • DRIVERS OF BIOBANKS GROWTH
  • RESISTORS OF BIOBANKS GROWTH
  • BIOBANKING TRENDS AND FORECAST
  • THE ROLE OF BIOBANKS IN FUTURE BIOMEDICAL DISCOVERIES

CHAPTER 4 OVERVIEW OF BIOBANK APPLICATIONS

  • TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • BIOMARKERS
  • TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.
  • TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 ($ MILLIONS/%)
  • OPPORTUNITIES IN CANCER
  • TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT
  • TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY
  • OPPORTUNITIES IN CARDIOVASCULAR DISEASE
  • TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR
  • OPPORTUNITIES IN NEUROLOGICAL DISEASES
    • THE BRAIN AND THE CENTRAL NERVOUS SYSTEM
    • TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
  • OPPORTUNITIES IN IMMUNOLOGY
    • AUTOIMMUNE DISEASES
    • TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY
    • SYSTEMIC LUPUS ERYTHEMATOSUS
    • ALZHEIMER'S DISEASE
  • OTHER OPPORTUNITIES RESULTING FROM BIOBANKS
    • TARGETED THERAPEUTICS
    • DIAGNOSTIC AND PROGNOSTIC TESTS
      • Diagnostic Tests
      • Prognostic Tests
    • DRUG DEVELOPMENT
    • DISEASE ETIOLOGY

CHAPTER 5 CURRENT BIOBANKS WORLDWIDE

  • OVERVIEW
  • TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009
  • TABLE 13 TYPES OF BIOBANKS
  • U.S. BIOBANKS
  • TABLE 14 MAJOR NHLBI COHORT STUDIES
  • TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
  • EUROPEAN BIOBANKS
    • THE UNITED KINGDOM
      • UK Biobank
      • Licensed Biobanks in The U.K.
      • TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016
      • TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)
      • Biobank and Biomolecular Resource Research Infrastructure
      • TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)
      • TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES
      • TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)
      • TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)
    • BIOBANKS IN NORTHERN EUROPE
      • Biobanks in Denmark
      • Biobanks in the Baltic Countries
    • INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD
      • Canadian Partnership for Tomorrow Project
      • Far East Biobanks
      • China Biobank
      • The Qatar Biobank
      • Middle East Biobanks

CHAPTER 6 DISEASE-BASED BIOBANKS

  • GROWTH IN DISEASE-BASED BIOBANKS
  • TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014
  • CANCER BIOBANKS
  • BIOBANKS FOR OTHER DISEASES
  • HEALTHY SAMPLE BIOBANKS
  • COLLABORATIVE NETWORKS
    • CORE UK
    • INTERNATIONAL GENOMICS CONSORTIUM
    • CANCER GENOME ATLAS
    • SEGMENT FORECAST

CHAPTER 7 POPULATION BASED BIOBANKS

  • INTRODUCTION
  • TYPES OF POPULATION BIOBANKS
  • COHORT STUDIES
  • TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009
  • FOUNDER POPULATION BIOBANKS
  • TABLE 24 FOUNDER POPULATION-BASED BIOBANKS
    • DECODE GENETICS
    • CARTAGENE
    • GENIZON BIOSCIENCES
    • JURILAB
  • NATIONAL POPULATION BIOBANKS
    • UK BIOBANK
    • LIFEGENE
    • ESTONIAN BIOBANK
    • LATVIAN BIOBANK
    • CANADIAN PARTNERSHIP FOR TOMORROW PROJECT
    • OTHER NATIONAL BIOBANKS

CHAPTER 8 FOR-PROFIT BIOBANK COMPANIES

  • CONTRACT BIOBANK AND SERVICE PROVIDERS
  • BIOMARKER DISCOVERY COMPANIES
  • PHARMACEUTICAL COLLECTIONS
  • RESEARCH COLLABORATIONS
  • CLINICAL TRIALS

CHAPTER 9 THE LIMITATIONS OF BIOBANKS

  • SAMPLE VARIABILITY
  • SAMPLE QUALITY
  • EFFORTS TO INCREASE HARMONIZATION
  • INITIATIVES TO IMPROVE BIOBANKS

CHAPTER 10 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS

  • INTRODUCTION
  • ROLE OF THE FOOD & DRUG ADMINISTRATION
  • CURRENT REGULATORY FRAMEWORK
  • INFORMED CONSENT
  • WITHDRAWAL AND OWNERSHIP
  • CONFIDENTIALITY
  • COMMERCIALIZATION
  • FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • EUROPEAN MEDICINES AGENCY
    • REGULATORY IMPACT ON DRUG SAFETY
  • INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING
    • APPROVED PATENT ANALYSIS
    • TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016
    • COMPETITIVE LANDSCAPE
    • LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING
    • TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
    • TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN
  • ETHICAL CONSIDERATIONS
    • SUMMARY
  • REGULATORY IMPLICATIONS

CHAPTER 11 BIOBANK MARKETS FORECAST BY SEGMENT AND REGION

  • SUMMARY
  • TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • GEOGRAPHIC MIX
  • TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)

CHAPTER 12 DETAILED DESCRIPTION OF THE USE OF BIOMARKERS

  • COLORECTAL CANCER
    • CETUXIMAB
    • PANITUMUMAB
    • ELESCLOMOL
    • HERCEPTIN
  • OTHER PREDICTIVE TESTS
  • TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
  • BREAST CANCER
    • MAMMAPRINT
    • TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009
    • ONCOTYPE DX
  • TEST ADOPTION
    • OTHER PROGNOSTIC TESTS
    • HORMONAL THERAPIES
    • TAXANES/ANTHRACYCLINES
  • TRIPLE NEGATIVE BREAST CANCER
  • OTHER NOVEL BIOMARKERS
  • LUNG CANCER
    • INTRODUCTION
    • PREDICTIVE TESTS
    • TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014
    • GEFITINIB
    • ERLOTINIB
  • OTHER PREDICTIVE TESTS
  • NOVEL THERAPIES
    • PROSTATE CANCER
    • OVARIAN CANCER
    • MALIGNANT MELANOMA
    • TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016
  • CARDIOVASCULAR
  • TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014
  • CENTRAL NERVOUS SYSTEM
  • TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013
  • TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009
  • IMMUNOLOGY- AUTOIMMUNE DISEASES
  • TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014
  • IMMUNOLOGY
    • BENLYSTA: HUMAN GENOME SCIENCES
    • EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI LILLY

CHAPTER 13 COMPANY ANALYSIS

  • ABBOTT LABORATORIES INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • AFFYMETRIX, INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • ASTERAND PLC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • ASTRAZENECA LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • BAYER SCHERING PHARMA AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • BIOCHAIN-GENOMICS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • BIOSTORAGE TECHNOLOGIES, INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • BOEHRINGER INGELHEIM GMBH
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • BRISTOL-MYERS SQUIBB CO
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • DAIICHI SANKYO COMPANY, LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • ELI LILLY AND COMPANY
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • EXIQON LIFE SCIENCES
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • GLAXOSMITHKLINE
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • JOHNSON & JOHNSON LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • MILLENNIUM PHARMACEUTICALS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • MERCK & CO.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • NOVARTIS AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • PFIZER INC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • F. HOFFMAN-LA ROCHE AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • SANOFI-AVENTIS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • SCIPAC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • TAKEDA PHARMACEUTICALS LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015
  • TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021
  • TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)
  • TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.
  • TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 ($ MILLIONS/%)
  • TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT
  • TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY
  • TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR
  • TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
  • TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY
  • TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009
  • TABLE 13 TYPES OF BIOBANKS
  • TABLE 14 MAJOR NHLBI COHORT STUDIES
  • TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
  • TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016
  • TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)
  • TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)
  • TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES
  • TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)
  • TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)
  • TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014
  • TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009
  • TABLE 24 FOUNDER POPULATION-BASED BIOBANKS
  • TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016
  • TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
  • TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN
  • TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)
  • TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
  • TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009
  • TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014
  • TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016
  • TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014
  • TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013
  • TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009
  • TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014
  • TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 ($ BILLIONS)
Back to Top